Table 5.
Analysis of “early event” (recurrence or death within ≤ 3 years from diagnosis) vs. no early event among those with at least 5 years of follow-up available.
| “Early event”* (n = 21) | No “early event” (n = 35) | P-value | |
|---|---|---|---|
| First diagnosis | — | — | 0.008 |
| PXA | 10 (47.6%) | 29 (82.9%) | — |
| PX-AF | 11 (52.4%) | 6 (17.1%) | — |
| Gender | — | — | 0.78 |
| Female | 8 (38.1%) | 16 (45.7%) | — |
| Male | 13 (61.9%) | 19 (54.3%) | — |
| Age | — | — | 0.26 |
| Pediatric (≤18) | 6 (28.6%) | 16 (45.7%) | — |
| Adult (>18) | 15 (71.4%) | 19 (54.3%) | — |
| Surgery type | — | — | 0.004 |
| N/A | 2 | 1 | — |
| Gross total resection (GTR) | 5 (26.3%) | 24 (70.6%) | — |
| Subtotal resection (STR)/biopsy only (BX) | 14 (73.7%) | 10 (29.4%) | — |
| Mitotic index (MI) | — | — | 0.02 |
| N/A | 3 | 4 | — |
| MI < 5/10HPF | 9 (50.0%) | 26 (83.9%) | — |
| MI ≥ 5/10 HPF | 9 (50.0%) | 5 (16.1%) | — |
| BRAF V600E mutation status | — | — | 0.07 |
| N/A | 3 | 11 | — |
| Nonmutant | 7 (38.9%) | 3 (12.5%) | — |
| Mutant | 11 (61.1%) | 21 (87.5%) | — |
| Radiotherapy | — | — | 0.003 |
| No | 9 (42.9%) | 29 (82.9%) | — |
| Yes | 12 (57.1%) | 6 (17.1%) | — |
| Chemotherapy | — | — | 0.005 |
| No | 8 (38.1%) | 27 (77.1%) | — |
| Yes | 13 (61.9%) | 8 (22.9%) | — |
*
Defined as presence of recurrence or death of disease within first 3 years of diagnosis.
MI = mitotic index; N/A = not available; PXA = pleomorphic xanthoastrocytoma; PXA-AF = pleomorphic xanthoastrocytoma with anaplastic features.